(1 - 16 von 19
)
CLNN.OQ - Clene Inc. | Stock Price & Latest News | Reuters
www.reuters.com
Robert Glanzman: Chief Medical Officer. Reed Neil Wilcox: Director, Co-Founder. Jonathan T. Gay: Independent Director. Shal Jacobovitz: Independent Director. › companies
GeNeuro Shareholders Approve all Proposals at AGM
www.finanznachrichten.de
Separately, GeNeuro announced the departure of its Chief Medical Officer (CMO) Dr Robert Glanzman, who will be returning to the US for family reasons at the end of June.
CNM-Au8 Shows Survival Benefit in HEALEY Trial
alsnewstoday.com
vor 4 Stunden — ... see a survival benefit in a broad population of people who had already been living with ALS for up to three years,” Robert Glanzman, MD, ... › news
Ginkgo Bioworks Acquires Adaptive Laboratory Evolution ...
dcnewsstation.com
vor 6 Stunden — Robert Glanzman, M.D., FAAN, Clene's Chief Medical Officer, said, “We are very pleased to see a survival benefit in a broad population of ... › ginkgo...
News & Media - GeNeuro
www.geneuro.com
Robert Glanzman at the 26th Annual Meeting of the European Charcot Foundation (November 2018) in Baveno, Italy. GeNeuro seals a €7.5 million financing ... › news-p...
ARUP Expert Joins Industry Peers to Explore How COVID
www.aruplab.com
— ... Experimental Pathology; Robert Glanzman, MD, chief medical officer of Clene Nanomedicine; and James McCullough, CEO of RenalytixAI. › news
Blocking Hidden Viral Protein Shows Promise for Treating ...
www.labiotech.eu
— ... and none have shown more than a modest impact on disease progression over the long term,” Robert Glanzman, the CMO of GeNeuro, told me. › multiple...
CNM-Au8 Found to Lessen Vision Problems in MS Patients in ...
multiplesclerosisnewstoday.com
— ... entire central nervous system,” Robert Glanzman, MD, Clene's chief medical officer, said in a company webcast announcing the results. › ...
CNM-Au8 Improved Brain's Energetic Profile in Parkinson's ...
parkinsonsnewstoday.com
— Robert Glanzman, MD, Clene's chief medical officer, said: “We see CNM-Au8's impact on brain bioenergetics as a breakthrough in the way ... › ...
Clene Inc.: Evidence for an ALS Survival Benefit with CNM ...
www.moneycontroller.co.uk
— ... RN3, Jacob Evan3, Jeremy Evan, PA-C3, Robert Glanzman, MD FAAN3, Michael T. Hotchkin3, Matthew C. Kiernan PhD, DSc, MBBS, FRACP, FAHMS. › ...
Phase 2 Parkinson's Trial of Potential Therapy for Dopaminergic...
parkinsonsnewstoday.com
CNM-Au, which showed promise in Parkinson's rats, including better dopaminergic neuron survival and motor function, is entering a Phase 2 trial in patients.
Clene Nanomedicine Presents Updated Long-Term Survival ...
www.streetinsider.com
— ... as a disease-modifying therapy for amyotrophic lateral sclerosis (ALS),” said Robert Glanzman, MD, FAAN, Clene's Chief Medical Officer. › Cle...
Clene Nanomedicine begins patient dosing in phase
www.pharmabiz.com
— ... motor neurons in ALS—the primary cause of clinical progression in ALS," said Robert Glanzman, MD, FAAN, Clene's chief medical officer. › News...
Clene Nanomedicine's Gold Nanocrystal Improves NAD+ ...
www.nmn.com
— ... failure is known to play a significant role in disease pathophysiology,” said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene. › news › cn...
Haunting Memories / Victim's family frustrated one year after ...
www.sfgate.com
— I try to not think about it," said Robert Glanzman, 73, a driver for the county office of education, who, during an interview at the ... › article
Nanocrystalline Gold Treatment Improves Survival in ...
practicalneurology.com
— ... the potential for CNM-Au8 as a disease-modifying therapy for ALS,” said Robert Glanzman, MD, FAAN, Clene's chief medical officer. › na...
sortiert nach Relevanz / Datum